Top Markets
Coin of the day
VectivBio Holding AG VectivBio Holding AG

VectivBio Holding AG

VECT
Clasificación en acciones #14766
VectivBio Holding AG is a clinical-stage biopharmaceutical firm committed to... VectivBio Holding AG is a clinical-stage biopharmaceutical firm committed to identifying, developing, and commercializing treatments for severe rare medical conditions. The company's primary therapeutic focus is apraglutide, a prolonged-acting synthetic peptide analog of glucagon-like peptide-2. This compound is currently in a Phase III clinical trial for individuals with short bowel syndrome-intestinal failure (SBS-IF), and is also being evaluated in a Phase II clinical trial for SBS-IF patients with colon-in-continuity anatomy. Furthermore, apraglutide is undergoing a Phase II clinical study for patients experiencing steroid-refractory gastrointestinal acute graft-versus-host disease (aGvHD). Founded in 2019, VectivBio's corporate headquarters are situated in Basel, Switzerland.
Precio por acción
$16.85
Última sincronización: 2023-07-07
Capitalización bursátil
$393.50M
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
CH
Comercio VectivBio Holding AG (VECT)

Categoría

Historial de dividendos de VectivBio Holding AG (VECT)
VectivBio Holding AG (símbolo bursátil: VECT) realizó un total de 0 pagos de dividendos.
La suma de todos los dividendos (ajustados por splits de acciones) es: 0.00
Rentabilidad por dividendo (TTM): 0
Pagos de dividendos de VectivBio Holding AG (VECT) desde 2026 hasta 2026
Pagos anuales de dividendos
Año Dividendo (ajustado por splits de acciones) Cambiar
Not enough data for the provided dates.
Lista de todos los pagos de dividendos
Año Dividendo Cambiar
Not enough data for the provided dates.
Pagos de dividendos de empresas similares o competidoras
Empresa Número de pagos de dividendos País
0.00%
US
0.00%
NL
64.00%
AU
0.00%
US
0.00%
CH